The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CTSO | -19.03% | -89.76% | -36.57% | -98% |
| S&P | +16.9% | +95.99% | +14.39% | +432% |
CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Princeton, NJ.
The biotech company took another step toward introducing a new way of performing bypass surgeries.
The company has priced its recently announced stock offering.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $9.62M | -2.8% |
| Gross Profit | $6.81M | 4.8% |
| Gross Margin | 70.85% | 5.1% |
| Market Cap | $80.14M | 109.9% |
| Market Cap / Employee | $0.54M | 0.0% |
| Employees | 149 | -19.9% |
| Net Income | $1.95M | 147.0% |
| EBITDA | -$3.17M | -13.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $10.20M | 20.6% |
| Accounts Receivable | $7.74M | -1.0% |
| Inventory | 3.7 | -14.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $26.56M | 0.8% |
| Short Term Debt | $0.78M | 89.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -19.23% | 29.0% |
| Return On Invested Capital | -46.77% | 10.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.55M | 67.9% |
| Operating Free Cash Flow | -$1.51M | 68.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 6.29 | 3.82 | 4.94 | 5.50 | 172.93% |
| Price to Sales | 2.16 | 1.40 | 1.76 | 2.51 | 144.27% |
| Price to Tangible Book Value | 6.29 | 3.82 | 7.45 | 7.38 | 266.22% |
| Enterprise Value to EBITDA | -26.34 | -11.06 | -21.93 | -32.48 | 60.27% |
| Return on Equity | -118.5% | -120.5% | -94.6% | -68.8% | -44.95% |
| Total Debt | $26.81M | $26.89M | $27.23M | $27.34M | 2.16% |
CTSO earnings call for the period ending September 30, 2020.
CTSO earnings call for the period ending June 30, 2020.
CTSO earnings call for the period ending March 31, 2020.
CTSO earnings call for the period ending June 30, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
